Teva Pharmaceutical Industries News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.10.13	Teva President & CEO Jeremy Levin To Step Down - Quick Facts (RTTNews)
16.10.13	Awareness Programs, Restructuring Efforts, Conference Calls, Marketing Authorization Withdrawal and Clinical Trial Commencement - Research Report on Lilly, Teva, Elan, Zoetis, and Boston Scientific (PR Newswire)
14.10.13	Teva Receives FDA Approval For Generic Version Of TOBI - Quick Facts (RTTNews)
10.10.13	Pre-market Movers For Oct 10 (AAPL, SIRI, CAFI, TEVA, PVR, IGTE, CTXS, RT) (RTTNews)
10.10.13	Teva To Cut 5000 Jobs, Sees $2 Bln In Annual Cost Savings By 2017 (RTTNews)
10.10.13	Teva To Cut 5,000 Jobs Globally - Quick Facts (RTTNews)
04.10.13	Teva Presents Additional Analyses Of Late-stage Allegro And Bravo Studies (RTTNews)
03.10.13	Teva Reports Further Results From Long-term, Open-label Extension Study Of GA (RTTNews)
30.09.13	Product Launches, Clinical Study Results, Historical Trials, Joint Lawsuits and Milestone Patient Enrollment - Research Report on Teva, Pacira, Novo Nordisk, Forest, and Amarin (PR Newswire)
27.09.13	Under AAAResearchReports.com Microscope: Zoetis Inc., Teva Pharma Industries Ltd, Covidien PLC, and Valeant Pharma Intl. Inc. (PR Newswire)
26.09.13	FDA Approvals, New Appointments, Positive Litigation Outcomes and Partnerships - Research Report on Edwards Lifesciences, Illumina, Teva, Alere, and Dr. Reddy's (PR Newswire)
24.09.13	Teva Announces Quartette™ (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets Now Available for the Prevention of Pregnancy in the United States (PR Newswire)
24.09.13	Teva Pharma Launches Generic ADENOSCAN In US - Quick Facts (RTTNews)
23.09.13	Teva Wins Azilect Patent Dispute Against Mylan - Quick Facts (RTTNews)
19.09.13	Legal Actions, Quarterly Dividends, Collaborations, and New Appointments - Research Report on Johnson & Johnson, Zoetis, Abbott, Teva Pharmaceuticals, and Baxter (PR Newswire)
17.09.13	Teva's TREANDA Injection Gets FDA Approval - Quick Facts (RTTNews)
16.09.13	Teva, Cancer Research Technology Sign R&D Alliance Agreement - Quick Facts (RTTNews)
29.08.13	AEZS Shifts Listing, AUXL Gets New Decision Date, Teva Hangs Up On RNN Deal (RTTNews)
28.08.13	Rexahn Pharma: Teva Decides Not To Exercise Its Option To License RX-3117 (RTTNews)
21.08.13	Technical Study: Zoetis Inc., Teva Pharma Industries Ltd, Covidien plc, and Valeant Pharma Intl. Inc. (PR Newswire)
12.08.13	Teva Pharma, Perrigo Announce U.S. Launch Of Generic Temozolomide - Quick Facts (RTTNews)
12.08.13	Financial Results Release, Management Changes, and Newly Issued Permits - Research Report on Valeant, Teva, Endo, Array, and Sequenom (PR Newswire)
09.08.13	Critical Alerts For Amazon, Teva Pharmaceuticals, Charles Schwab, VMware, and Level 3 Communications Released By InvestorsObserver (PR Newswire)
06.08.13	Strong Sales, Diversified Portfolio, and R&D Progress Boost Growth - Research Report on Teva, Auxilium, Nektar, Anika, and Vical (PR Newswire)
01.08.13	Teva Q2 Profit Meets Estimates, While Mylan Profit Beats View; But Revenues Miss (RTTNews)
01.08.13	Teva Q2 Adj. Profit Matches View, But Revenues Miss - Quick Facts (RTTNews)
01.08.13	Earnings Watch For August 1 (CAH, PG, KRFT, COP, XOM, LNKD) (RTTNews)
29.07.13	English Appeal Court Rules In Favor Of Teva In Copaxone Patent Case (RTTNews)
25.07.13	Teva, Lonza To Discontinue Biosimilars Collaboration (RTTNews)
23.07.13	FDA Designations to Development Programs and Quarterly Financial Results Schedules - Research Report on Valeant, Elan, Alkermes, Teva and Gilead (PR Newswire)
18.07.13	Teva Found On Summary Judgment To Infringe Mylan Patent For Perforomist (RTTNews)
18.03.10	Teva to Acquire ratiopharm (Businesswire)
17.03.10	Teva Provides Update on Generic Temodar® (Businesswire)
22.01.10	Court of Appeals Affirms Favorable Decision Regarding Generic Prevacid® SoluTab (Businesswire)
07.01.10	Teva Announces Settlement Agreements with AstraZeneca Regarding Generic Prilosec® and Nexium® (Businesswire)
10.09.09	COPAXONE® Significantly Reduced Disease Severity in Long-Term Treated Multiple Sclerosis Patients (Businesswire)
08.09.09	New Teva Data Highlights Advances in MS Treatment Research (Businesswire)
13.07.09	Plan B® One-Step—New FDA-Approved One-Pill Emergency Contraceptive (Businesswire)
02.04.09	Teva Introduces First Generic Adderall XR® Capsules in the United States (Businesswire)
17.03.09	Study Demonstrates That QVAR® is More Likely to Achieve Successful Asthma Control with Less Exacerbations (Businesswire)
17.02.09	Teva Reports Record Full Year 2008 and Fourth Quarter Results (Businesswire)
12.02.09	Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA (Businesswire)
27.01.09	Teva to Report Fourth Quarter and Full Year 2008 Financial Results on February 17, 2009 (Businesswire)
18.11.08	Economist Finds Flaws in 14-Year Data Exclusivity Claim for Biogenerics (Businesswire)
18.11.08	Teva Completes Enrollment in Laquinimod Phase III Clinical Trial (Businesswire)
07.11.08	Teva Provides Update on Generic Prevacid(R) Litigation (Businesswire)
23.09.08	Teva's ProAir(R) HFA, the Market Leading Albuterol Inhaler, Receives New Pediatric Indication (Businesswire)
18.09.08	Longest Prospective Study in MS Confirmed Robust Clinical Benefits and Safety of COPAXONE(R) (Businesswire)
12.05.08	Teva to Present at the Bank of America Health Care Conference (Businesswire)
06.05.08	Teva Reports First Quarter 2008 Results (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.75	0.89 %	K V
Nestle	76.36	0.69 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	78.00	0.49 %	K V
Roche Hldg G	252.50	0.44 %	K V
CieFinRichemont	121.90	-0.37 %	K V
Sika	226.60	-0.87 %	K V
ABB	49.02	-1.05 %	K V
Lonza Grp	517.00	-2.64 %	K V
Logitech Intl	70.06	-2.67 %	K V

mehr

27.11.24		Minuszeichen in New York: Dow Jones beendet die Sitzung im Minus
27.11.24		Dow Jones aktuell: Dow Jones legt nachmittags den Rückwärtsgang ein
27.11.24		Schwacher Wochentag in New York: Dow Jones verliert am Mittwochmittag
27.11.24		Mittwochshandel in London: FTSE 100 legt zum Handelsende zu
27.11.24		STOXX 50 aktuell: STOXX 50 zeigt sich zum Handelsende schwächer
27.11.24		Starker Wochentag in Zürich: SMI zum Handelsende freundlich
27.11.24		Schwacher Handel: SLI zum Handelsende im Minus
27.11.24		Novartis-Aktie höher: EU-Zulassung für Kisqali - Funktion des Schweizer Länderpräsidenten gestrichen

27.11.24

Minuszeichen in New York: Dow Jones beendet die Sitzung im Minus

27.11.24

Dow Jones aktuell: Dow Jones legt nachmittags den Rückwärtsgang ein

27.11.24

Schwacher Wochentag in New York: Dow Jones verliert am Mittwochmittag

27.11.24

Mittwochshandel in London: FTSE 100 legt zum Handelsende zu

27.11.24

STOXX 50 aktuell: STOXX 50 zeigt sich zum Handelsende schwächer

27.11.24

Starker Wochentag in Zürich: SMI zum Handelsende freundlich